Delving into the Latest Updates on Levocetirizine Hydrochloride with Synapse

Overview

Basic Info

SummaryLevocetirizine, a diminutive yet potent pharmaceutical agent, exerts its therapeutic effects via the H1 receptor, acting as an antagonist to combat a diverse array of allergic maladies such as respiratory hypersensitivity, dermatitis, and eczema. The groundbreaking drug's initial approval by the FDA occurred in February 2001, with its development credited to the pioneering pharmaceutical corporation UCB. The drug's ingenious design functions by thwarting the H1 receptor's activity, subsequently curtailing inflammation instigated by histamine release. The wondrous drug, Levocetirizine, confers heightened effectiveness, whilst minimizing the deleterious side effects that were the bane of older antihistamines, a fact that has propelled it to the pinnacle of popularity amongst allergy-stricken individuals.

Drug Type

Small molecule drug

Synonyms

2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid, Airitis, Elzinex

+ [21]

Target

H1 receptor

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [3]

Active Indication

Respiratory HypersensitivityHypersensitivityDermatitis+ [9]

Inactive Indication

AnaphylaxisAsthmaCough+ [5]

Originator Organization

UCB SA

Active Organization

Chongqing Huapont Pharmaceutical Co. Ltd.

UCB SA

GSK Plc

+ [2]

Inactive Organization

UCB Pharma GmbHUCB Pharma SADr. Reddy's Laboratories Ltd. (Russia)

Drug Highest PhaseApproved

First Approval Date

DE (16 Aug 2001),

Rhinitis, Allergic, PerennialRhinitis, Allergic, SeasonalRhinitis, Allergic+ [1]

Regulation-

Login to view timeline

Structure

Molecular FormulaC21H27Cl3N2O3

InChIKeyPGLIUCLTXOYQMV-GHVWMZMZSA-N

CAS Registry130018-87-0

主要目的：以康芝药业股份有限公司生产的盐酸左西替利嗪颗粒为受试制剂，以Sanofi Aventis US LLC持证，Chattem, Inc., a Sanofi Company生产的盐酸左西替利嗪口服溶液为参比制剂，考察在健康受试者中的空腹和餐后条件下受试制剂和参比制剂的吸收速度和吸收程度，评价受试制剂和参比制剂是否具有生物等效性。次要目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary purpose: To use the levocetirizine hydrochloride granules produced by Kangzhi Pharmaceutical Co., Ltd. as the test preparation and the levocetirizine hydrochloride oral solution produced by Chattem, Inc., a Sanofi Company, licensed by Sanofi Aventis US LLC, as the reference preparation, to investigate the absorption rate and extent of the test preparation and the reference preparation under fasting and postprandial conditions in healthy subjects, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date12 Oct 2024

Sponsor / Collaborator

Honz Pharmaceutical Co., Ltd.

100 Clinical Results associated with Levocetirizine Hydrochloride

Login to view more data

100 Translational Medicine associated with Levocetirizine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Levocetirizine Hydrochloride

Login to view more data

582

Literatures (Medical) associated with Levocetirizine Hydrochloride

01 Dec 2024·JOURNAL OF ASTHMA

Montelukast treatment response according to eosinophil-derived neurotoxin level in children with allergic rhinitis

Article

Author: Lee, Yong Ju ; Callaway, Zak ; Ma, Hyo-Sun ; Kim, Chang-Keun

BACKGROUND:

Eosinophil-derived neurotoxin (EDN) is an important biomarker of eosinophilic inflammation.

METHODS:

This study evaluated Montelukast treatment response according to EDN concentration in children with perennial allergic rhinitis (PAR). Fifty-two children with PAR were recruited and took a combination of Montelukast (5mg) and Levocetirizine (5mg) "Mont/Levo Group" or only Montelukast (5mg) "Mont Group" for 4 weeks. All caregivers were instructed to record rhinitis symptoms for 4 weeks. EDN was measured before and after treatment.

RESULTS:

Daytime nasal symptom scores (DNSS) significantly decreased in both the Mont/Levo (p = 0.0001; n = 20) and Mont Group (p < 0.0001; n = 20), but there were no significant differences between the two groups. EDN concentration also significantly decreased after treatment in both groups (p < 0.0001 and p < 0.001, respectively). For secondary analysis, children with a high initial EDN concentration (EDN ≥ 53 ng/mL) were placed in the "High EDN Group", while those with a lower initial EDN concentration (EDN < 53 ng/mL) were put in the "Low EDN Group". Both groups experienced significant reductions in DNSS after either treatment regimen (p < 0.0001 and p = 0.0027, respectively) but the High EDN Group had greater reductions. EDN concentrations in the High EDN Group decreased significantly from either treatment (p < 0.0001).

CONCLUSION:

We found that children with AR and a high serum EDN concentration may respond well to Montelukast treatment. A therapeutic strategy using EDN concentrations in patients with AR to evaluate therapeutic response may help improve quality of care.

01 Nov 2024·PSYCHOPHARMACOLOGY

5-hydroxytryptamine 2C/1A receptors modulate the biphasic dose response of the head twitch response and locomotor activity induced by DOM in mice

Article

Author: Wang, Longyu ; Yao, Yishan ; Wang, Xiaoxuan ; Su, Ruibin ; Zhou, Peilan ; Zhu, Huili

RATIONALE:

The phenylalkylamine hallucinogen (-)-2,5-dimethoxy-4-methylamphetamine (DOM) exhibits an inverted U-shaped dose-response curve for both head twitch response (HTR) and locomotor activity in mice. Accumulated studies suggest that HTR and locomotor hyperactivity induced by DOM are mainly caused by the activation of serotonin 5-hydroxytryptamine 2 A receptor (5-HT_2A receptor). However, the mechanisms underlying the biphasic dose response of HTR and locomotor activity induced by DOM, particularly at high doses, remain unclear.

OBJECTIVES:

The primary objective of this study is to investigate the modulation of 5-HT_2A/2C/1A receptors in HTR and locomotor activity, while also exploring the potential receptor mechanisms underlying the biphasic dose response of DOM.

METHODS:

In this study, we employed pharmacological methods to identify the specific 5-HT receptor subtypes responsible for mediating the biphasic dose-response effects of DOM on HTR and locomotor activity in C57BL/6J mice.

RESULTS:

The 5-HT_2A receptor selective antagonist (R)-[2,3-di(methoxy)phenyl]-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol (M100907) (500 µg/kg, i.p.) fully blocked the HTR at every dose of DOM (0.615-10 mg/kg, i.p.) in C57BL/6J mice. M100907 (50 µg/kg, i.p.) decreased the locomotor hyperactivity induced by a low dose of DOM (0.625, 1.25 mg/kg, i.p.), but had no effect on the locomotor hypoactivity induced by a high dose of DOM (10 mg/kg) in C57BL/6J mice. The 5-HT_2C antagonist 6-chloro-5-methyl-1-[(2-[2-methylpyrid-3yloxy]pyrid-5yl)carbamoyl]indoline (SB242084) (0.3, 1 mg/kg, i.p.) reduced the HTR induced by a dose of 2.5 mg/kg DOM, but did not affect the response to other doses. SB242084 (1 mg/kg, i.p.) significantly increased the locomotor activity induced by DOM (0.615-10 mg/kg, i.p.) in mice. The 5-HT_1A antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]N-(2-pyridinyl) cyclohexane carboxamide maleate (WAY100635) (1 mg/kg, i.p.) increased both HTR and locomotor activity induced by DOM in mice. The 5-HT_1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (1 mg/kg, i.p.) significantly reduced both the HTR and locomotor activity induced by DOM in mice. Additionally, pretreatment with the Gα_i/o inhibitor PTX (0.25 µg/mouse, i.c.v.) enhanced the HTR induced by DOM and attenuated the effect of DOM on locomotor activity in mice.

CONCLUSIONS:

Receptor subtypes 5-HT_2C and 5-HT_1A are implicated in the inverted U-shaped dose-response curves of HTR and locomotor activity induced by DOM in mice. The biphasic dose-response function of HTR and locomotor activity induced by DOM has different mechanisms in mice.

02 Oct 2024·Expert Review of Clinical Pharmacology

Analyzing the clinical efficacy and safety of levocetirizine based on its receptor occupancy, intraclass comparison and role in the treatment of CSU: an AROG consensus statement

Review

Author: Bansal, Shivani ; Ghate, Sunil ; Jain, Akshay ; Agarwal, Dhruv Premy ; Patel, Krina ; Hazarika, Neirita ; Rao, Narayan ; Sandhu, Jaspriya ; Girdhar, Mukesh ; Srinivasan, CR ; Sardana, Kabir ; Haq, Rizwan

INTRODUCTION:

Chronic spontaneous urticaria (CSU) is characterized by urticaria persisting for more than 6 weeks. Antihistamines, notably sgAH (second generation antihistamines) are the first line of treatment for CSU.

AREAS COVERED:

This consensus aimed to review the existing research on receptor occupancy of antihistamines, including levocetirizine, and translate its implications in the treatment of CSU. The consensus deliberations were under the banner of the Antihistamine Receptor Occupancy Group (AROG) from India, an expert panel of 12 dermatologists with a mix of institutional and practitioner backgrounds. This group analyzed the existing translational research on the receptor occupancy of levocetirizine to establish the clinical efficacy and safety of levocetirizine in the treatment of CSU using the grading of recommendations assessment, development, and evaluation (GRADE) method vis-a-vis the varied SGAH.

EXPERT OPINION:

SGAH constitute the first step in the therapeutic ladder for managing CSU. Levocetirizine has high bioavailability, high affinity and occupancy of the H1 receptor, rapid onset of action, limited distribution and minimal hepatic metabolism. It exhibits significant anti-inflammatory effects at clinically relevant concentrations. The marked receptor occupancy translates to enhanced efficacy as compared to similarly dosed SGAH with the lower cost making it an appropriate drug for chronic use. Receptor occupancy should be the basis of intra-class head-to-head trials in CSU.

7

News (Medical) associated with Levocetirizine Hydrochloride

02 Dec 2024

·www.pharmaceutical-technology.com

CBC acquires UCB’s neurology and allergy business in China

The new company aims to deliver quality treatments and address evolving neurology treatment needs in the country. Credit: Volha_R/Shutterstock. CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge’s ( UCB ) mature neurology and allergy business in China for $680m. The move comes after UCB agreed to sell and license its business in August 2024. The deal encompasses UCB’s Zhuhai manufacturing site and its brands Xyzal, Keppra, Zyrtec, Vimpat and Neupro. They are set to be the cornerstone assets for CBC as it develops an integrated central nervous system (CNS) biopharma platform in China. Working alongside Mubadala, CBC plans to leverage its platform synergies, investor-operator approach and healthcare expertise, to optimise operations, foster innovation and expand its reach to benefit more patients in the region. The new entity formed from this acquisition called NeuroGen Pharma is set to offer neuro healthcare innovation services. It will be spearheaded by a management team with a solid background in the biopharma industry, which is expected to ensure a seamless transition and drive future growth. The company aims to deliver quality treatments and address the evolving neurology treatment needs in the country. The acquired portfolio reported combined net sales of €131m ($138m) in 2023. The strategic acquisition is part of a broader partnership between CBC and Mubadala, which also includes their joint investment in the $315m fundraising round for Hasten and an investment in CBC Healthcare Infrastructure Platform’s first life science real assets venture. CBC Group CEO Fu Wei stated: “There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. “This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today’s healthcare investing market.”

Acquisition

30 Nov 2024

·www.prnewswire.com

CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China

CBC Group and Mubadala acquire UCB's mature neurology and allergy business in China for US$680 million. New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry. Strategic acquisition under CBC's buyout strategy expected to drive significant value creation and positive patient outcomes through CBC's proven investor-operator approach and solution. SINGAPORE, Nov. 30, 2024 /PRNewswire/ -- CBC Group ("CBC"), Asia's largest healthcare-dedicated asset management firm headquartered in Singapore, has completed the strategic acquisition of global biopharmaceutical company UCB's mature neurology and allergy business in China, in partnership with Mubadala Investment Company, the Abu Dhabi based global investment company. The acquisition marks another successful transaction under CBC's buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in China while expanding CBC's portfolio within the region's dynamic pharmaceutical market. The transaction, valued at US$680 million, includes UCB's well-known brands Keppra®, Vimpat®, Neupro®, Zyrtec®, Xyzal®, and the Zhuhai manufacturing site. The well-established and trusted medicine portfolio will serve as an anchor asset as CBC builds out a leading integrated central nervous system (CNS) biopharma platform in China, where the market size has reached US$33 billion1. Beyond strengthening CBC's presence in the rapidly growing Chinese healthcare market, the acquisition also enhances the firm's capabilities in meeting the rising demand for neurology and allergy treatments in the wider region. In collaboration with Mubadala, CBC will tap on its proprietary investor-operator approach, deep healthcare expertise and platform synergies to drive operational efficiencies, innovation and scale to benefit more patients across the region. Fu Wei, Chief Executive Officer of CBC Group, said, "There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today's healthcare investing market. Together, we are making a profound impact on the industry by harnessing our combined expertise and capital to not only enhance patient outcomes but also build value for our stakeholders. Leveraging our joint strengths, we are poised to capitalize on synergies and deploy hands-on strategic guidance to make significant strides in CNS market access and innovation." Named "NeuroGen Pharma", the new company embodies what CBC and Mubadala envision for neuro healthcare innovation. The company will be led by a deep and experienced management team with an extensive track record in the biopharma industry, ensuring a smooth transition to propel into the next phase of growth. NeuroGen Pharma is expected to deliver quality treatments to a wider reach of patients and play an important role in addressing the evolving neurology treatment needs in China. The company aims to leverage innovative therapies and cutting-edge research to enhance patient outcomes and shape the future of neurology care in the region. Combined net sales for the acquired portfolio in this transaction were Euro131 million in 2023. The strategic acquisition builds on CBC's collaboration with Mubadala, which includes their investment in CBC Healthcare Infrastructure Platform's (HIP) first life science real assets venture and the joint investment in the US$315 million fundraising round for CBC-backed Hasten, a leading pharmaceutical company. Mohamed Albadr, Head of Asia at Mubadala, said, "We are thrilled to partner with CBC Group to support the growth and development of NeuroGen Pharma as it scales to a leading entity in China and delivers transformative medicines to patients. Built on a strong foundation of proven therapies and driven by innovation and cutting-edge research, the company is uniquely positioned to address the growing need for advanced neurology and allergy treatments while aligning with our commitment to enhancing access to care and growth in the healthcare system." Jean-Christophe Tellier, CEO at UCB, said, "In the short term, UCB is exploring the launch of novel medicines in immunology, neurology, and rare diseases in China. Our dedication to serving patients with unmet needs in China remains steadfast. Building on our 28-year presence in the country, we are committed to driving patient outcomes through continued collaboration with local partners and fostering innovation. We are convinced that the CBC Group and Mubadala are the ideal partners to advance the medicine portfolio and continue to improve the lives of people living with neurology and allergy diseases in mainland China." About CBC Group Headquartered in Singapore, CBC Group is Asia's largest healthcare-dedicated asset management firm, with an AUM of US$9 billion. With a diversified, multi-product strategy, CBC Group is focused on platform-building, buyout, private credit and royalties, and real estate, across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services. We are committed to creating lasting value by integrating global innovations and talents. Partnering with the world's top entrepreneurs and scientists, our unique "investor-operator" approach has empowered leading healthcare companies to widen access to affordable medical care, catalyse innovations, and improve efficiencies in fulfilling unmet medical needs worldwide. For more information on CBC Group, please visit . Connect with us on LinkedIn (CBC Group). About UCB UCB, Brussels, Belgium () is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news. About Mubadala Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi. Mubadala's $302 billion (AED 1,111 billion) portfolio spans six continents with interests in multiple sectors and asset classes. We leverage our deep sectoral expertise and long-standing partnerships to drive sustainable growth and profit, while supporting the continued diversification and global integration of the economy of the United Arab Emirates. For more information about Mubadala Investment Company, please visit: . WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Acquisition

03 Sep 2024

·www.echemi.com

UCB sells mature Chinese business in a package, Middle East and Singapore capital jointly take over for nearly 5 billion yuan

UCB, a Belgian-based biopharmaceutical company, will sell its mature neurology and allergy business in China to Singapore-based asset management group CBC and Abu Dhabi-based investment company Mubadala for US$680 million (about 4.843 billion yuan). The transaction includes epilepsy drug brands Keppra and Vimpat, Parkinson's drug brand Neupro, allergy drug brands Zyrtec and Xyzal, and the company's Zhuhai production base. According to UCB, the net sales of these drugs in China in 2023 totaled 131 million euros. The transaction is subject to customary closing conditions and is expected to be completed in the fourth quarter of 2024. Jean-Christophe Tellier, CEO of UCB, said: "In the short term, UCB is exploring the launch of new medicines in the fields of immunology, neurology and rare diseases in China. We remain steadfast in our commitment to serving patients with unmet needs in China. With our 28 years of operating experience in China, we are committed to driving patient outcomes through continued collaboration with local partners and promoting innovation." CBC Group CEO Wei Fu said: "Over the past decade, China has seen growing demand for central nervous system (CNS) products, and by leveraging CBC's unique investor-operator model, we are excited to leverage our expertise, resources and platform synergies to meet these evolving needs and create value for our stakeholders." Mohamed Albadr, Head of Mubadala China, said: "We are pleased to partner with CBC Group to support the next phase of UCB's platform development to become a leading entity in China and deliver transformative medicines to the market. The company's commitment to clinical excellence and innovation is consistent with our commitment to improving access to healthcare services and promoting the development of healthcare systems." UCB said the transaction will enable it to focus on innovation and collaboration, ensuring that its strategic goals are aligned with the evolving needs of the Chinese market.

100 Deals associated with Levocetirizine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08118	-	R06AE09	DB06282

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Respiratory Hypersensitivity	US	Chattem, Inc.	31 Jan 2017
Hypersensitivity	JP	GSK Plc	31 Oct 2010
Dermatitis	JP	GSK Plc	27 Oct 2010
Eczema	JP	GSK Plc	27 Oct 2010
Prurigo	JP	GSK Plc	27 Oct 2010
Pruritus	JP	GSK Plc	27 Oct 2010
Chronic Urticaria	CN	Chongqing Huapont Pharmaceutical Co. Ltd.	21 Jan 2004
Conjunctivitis, Allergic	CN	Chongqing Huapont Pharmaceutical Co. Ltd.	21 Jan 2004
Rhinitis, Allergic	DE	UCB SA	16 Aug 2001
Rhinitis, Allergic, Perennial	DE	UCB SA	16 Aug 2001
Rhinitis, Allergic, Seasonal	DE	UCB SA	16 Aug 2001
Urticaria	DE	UCB SA	16 Aug 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anaphylaxis	Phase 3	-	UCB Pharma GmbH	01 Aug 2003
Seasonal rhinitis	Phase 3	-	UCB Pharma GmbH	01 Aug 2003
Asthma	Phase 3	-	UCB Pharma SA	20 Mar 2002
Dermatitis, Atopic	Phase 3	-	UCB Pharma SA	20 Mar 2002
Cough	Phase 2	-	UCB SA	01 Dec 2001
Pruritis (itchy skin)	Phase 1	CN	Chongqing Huapont Pharmaceutical Co. Ltd.	12 Sep 2017
Perennial allergic rhinitis with seasonal variation	Phase 1	JP	GSK Plc	02 May 2012
Fasting	Phase 1	IN	Dr. Reddy's Laboratories Ltd. (Russia)	01 Dec 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03555890 (CTgov)	Phase 1	Rhinitis	72	Levocetirizine (Part 1: Levocetirizine ODT 5 mg)	irakcgogcg(zbksoagove) = yqtmrdpmfc fptbpnyxxb (meijgrzhos, rgcbyshbsj - nzmrpprzat) View more	-	12 Sep 2019
				Levocetirizine (Part 1: Levocetirizine IRT 5 mg)	irakcgogcg(zbksoagove) = qinhkmxikq fptbpnyxxb (meijgrzhos, hecdpqtzxf - znmqcxwnfg) View more
NCT01722162 (ASCO_GI2015) Manual	Phase 2	Metastatic Colorectal Carcinoma	36	levocetirizine+capecitabine+bevacizumab	yyprnraibz(zkmugxuqno) = harocylskr zepcovevxt (toqeghvxvr ) View more	Positive	20 Jan 2015
NCT01622283 (Pubmed \| J Drug Assess)	Phase 1	-	20	Levocetirizine oral solution 5mg	jlsrrtolnx(xuxloxwzqd) = zjwlabfvoc tjpmcgepqm (pxcewceysk ) View more	-	01 Jan 2014
				Cetirizine dry syrup 10mg	jlsrrtolnx(xuxloxwzqd) = kefcsntymq tjpmcgepqm (pxcewceysk ) View more
NCT01563081 (CTgov)	Phase 3	Pruritus \| Rhinitis, Allergic	60	Levocetirizine (Levocetirizine: >=6 Months and <12 Months Old)	xifmdoyapo(goukiybipg) = gvlhjuizcz jrhxdecyhg (mnhcpkpnmm, soovjpxske - jgjohaitdu) View more	-	03 Jun 2013
				Levocetirizine (Levocetirizine: >=12 Months and <24 Months Old)	xifmdoyapo(goukiybipg) = gwihwcladu jrhxdecyhg (mnhcpkpnmm, uzwiiscfat - ihvzaekndj) View more
AAAAI2011	Not Applicable	Rhinitis, Allergic	-	Levocetirizine	imlxvhxlox(nqvdudkfwt) = sayixovtfw fjjqsvgysd (hotgrvmwpm, -8.1% - -7.9%) View more	Positive	01 Feb 2011
AAAAI2010	Not Applicable	Rhinitis, Allergic, Perennial nNO \| nEos	31	Oral Levocetirizine (LC) 5mg	ojgpnpotzu(bcjyodisuh) = ceklltvwvp kxdjbhvakd (yzlgobwrfy )	Positive	01 Feb 2010
NCT00653224 (CTgov)	Phase 4	Rhinitis, Allergic, Seasonal	580	placebo	rlehxfmdfk(etfoqzflfn) = kxjhjebnpt iyquugojrl (wzvaaxlobv, plbmsmyyxj - enunxrchtc) View more	-	17 Nov 2009
NCT00375713 (CTgov)	Phase 3	Eczema	466	Placebo-Cetirizine+Levocetirizine+Standard topical steroid (1% hydrocortisone) ointment (Levocetirizine)	nmammlkaqj(vmegkwozyl) = hdfckvnscd axhdfaicpu (brtxftvknt, gzytmhnhqs - pwbobljqda) View more	-	14 Oct 2009
				Placebo-Levocetirizine+Cetirizine+Standard topical steroid (1% hydrocortisone) ointment (Cetirizine)	nmammlkaqj(vmegkwozyl) = xlcimdgbtp axhdfaicpu (brtxftvknt, lvhfgwgqyy - vasewwpsit) View more
NCT00628108 (BALL, CTgov)	Phase 3	Rhinitis, Allergic \| Chronic Urticaria	69	Placebo (Placebo)	ddtcpspibk(zsgongiund) = xsqtnnuikv drcehjzkix (plxiwjcyoe, tdckhlcczy - uaoiisdsay) View more	-	14 Oct 2009
				Levocetirizine 1.25 mg (Levocetirizine)	ddtcpspibk(zsgongiund) = rgwrnmtwyq drcehjzkix (plxiwjcyoe, vrawzgvvrl - iubdmqkvbb) View more
NCT00619801 (PAL, CTgov)	Phase 3	Rhinitis, Allergic \| Chronic Urticaria	173	Placebo (Placebo)	bwzalgttec(vwwztqdzkv) = deyokogyge itjsccktii (iyiifsuwxr, gomnowsrqx - cyehsabqej) View more	-	04 Sep 2009
				Levocetirizine (Levocetirizine)	bwzalgttec(vwwztqdzkv) = jysikibhjp itjsccktii (iyiifsuwxr, xztxhkgock - rjjwxcydsp) View more